Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 2, No. 3, 2009
Issue release date: October 2009
Section title: Minireview
Free Access
J Nutrigenet Nutrigenomics 2009;2:140–148

Polyunsaturated Fatty Acids and Cardiovascular Disease: Implications for Nutrigenetics

Allayee H.a, b · Roth N.a · Hodis H.N.a, c
aDepartment of Preventive Medicine, bInstitute for Genetic Medicine and cAtherosclerosis Research Unit, Keck School of Medicine, University of Southern California, Los Angeles, Calif., USA
email Corresponding Author

Hooman Allayee, PhD

Department of Preventive Medicine, USC Keck School of Medicine

2250 Alcazar Street, CSC 206

Los Angeles, CA 90033 (USA)

Tel. +1 323 442 1736, Fax +1 332 442 2764, E-Mail hallayee@usc.edu

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Cardiovascular disease (CVD) arises as a result of genetic predisposition in the context of a disease-promoting environment. While several risk factors have been identified for CVD, such as elevated serum lipid levels and hypertension, most of the genes identified thus far do not appear to involve such ‘conventional’ risk factors. Moreover, the interactions between genes and environment, such as a diet high in certain fats, adds another level of complexity to CVD and renders identification of the underlying genetic factors even more difficult. Polyunsaturated fatty acids (PUFAs), such as the ω–6 and ω–3 fatty acids, which have multiple roles in membrane structure, lipid metabolism, blood clotting, blood pressure, and, in particular, inflammation, have been linked to the reduction in CVD. Linoleic (ω–6) and α-linolenic acid (ω–3) are essential fatty acids that can be converted into long-chain PUFAs, such as arachidonic acid (AA) and eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA), respectively. These long-chain PUFAs are metabolized by enzymatically catalyzed systems via cyclooxygenases and lipoxygenases. The 5-lipoxygenase (5-LO)/leukotriene (LT) biosynthesis pathway has been biochemically and genetically associated with CVD traits in mice and humans, particularly in the context of dietary AA and EPA/DHA. In this review, we summarize the biochemical metabolism of ω–3 and ω–6 PUFAs, evaluate the evidence for genetic and nutrigenetic contributions of 5-LO pathway genes to CVD, and discuss the potential of future studies that could identify other gene-dietary interactions between PUFAs and CVD traits.

© 2009 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Minireview

Published online: September 23, 2009
Issue release date: October 2009

Number of Print Pages: 9
Number of Figures: 3
Number of Tables: 2

ISSN: 1661-6499 (Print)
eISSN: 1661-6758 (Online)

For additional information: http://www.karger.com/JNN

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.